COVID Vaccine Sputnik V Manufacturer Hits Upper Circuit, Secures Rs 127 Crore Order from UNICEF – FIIs and DIIs Increase Stake
COVID Vaccine Sputnik V Manufacturer Hits Upper Circuit, Secures Rs 127 Crore Order from UNICEF – FIIs and DIIs Increase Stake

COVID Vaccine Sputnik V Manufacturer Hits Upper Circuit, Secures Rs 127 Crore Order from UNICEF – FIIs and DIIs Increase Stake

The company’s shares have delivered an impressive return of over 220 per cent in the past year.

Rakesh Deshmukh Article rating: 5.0

In Q2FY25 the company reported a net profit of Rs 4.71 crore compared to a loss of Rs 8.29 crore

Top gaining stocks: These healthcare stocks surged over 10 per cent despite a sharp decline in domestic markets!
Top gaining stocks: These healthcare stocks surged over 10 per cent despite a sharp decline in domestic markets!

Top gaining stocks: These healthcare stocks surged over 10 per cent despite a sharp decline in domestic markets!

The only sector which was least affected today was the BSE Healthcare Index, which plunged 1.18 per cent to Rs 23,493.96, despite a sharp decline in the domestic market.

Kiran Shroff Article rating: 4.3

The only sector which was least affected today was the BSE Healthcare Index, which plunged 1.18 per cent to Rs 23,493.96, despite a sharp decline in the domestic market.

Shilpa Biologicals join hands with Mylab to enter in vaccine and personalised therapeutics business
Shilpa Biologicals join hands with Mylab to enter in vaccine and personalised therapeutics business

Shilpa Biologicals join hands with Mylab to enter in vaccine and personalised therapeutics business

Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Ltd, has announced a strategic tie-up with Mylab Discovery Solutions, India’s leading diagnostic solutions provider.

Sayali Kotwal Article rating: 5.0

Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Ltd, has announced a strategic tie-up with Mylab Discovery Solutions, India’s leading diagnostic solutions provider. With this association, Shilpa Medicare expects to venture into the vaccine and therapeutics segment

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual
BSE Enlistment No. 5307
View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual
BSE Enlistment No. 1346
View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Conditions | Privacy Statement | WhiteList